[Should all patients with traumatic brain injury receive tranexamic acid?]

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Transliterated Title:
      Tranexamsyra till alla med akut traumatisk hjärnskada?
    • Source:
      Publisher: Sveriges Lakarforbund Country of Publication: Sweden NLM ID: 0027707 Publication Model: Electronic Cited Medium: Internet ISSN: 1652-7518 (Electronic) Linking ISSN: 00237205 NLM ISO Abbreviation: Lakartidningen Subsets: MEDLINE
    • Publication Information:
      Original Publication: Stockholm : Sveriges Lakarforbund
    • Subject Terms:
      Antifibrinolytic Agents*/adverse effects ; Brain Concussion* ; Brain Injuries, Traumatic*/complications ; Brain Injuries, Traumatic*/drug therapy ; Tranexamic Acid*/adverse effects; Double-Blind Method ; Humans ; Randomized Controlled Trials as Topic
    • Abstract:
      Traumatic brain injury (TBI) is a leading cause of death and disability. Progressive intracranial bleeding is common in TBI and worsens outcome. The multicentre, randomized placebo-controlled CRASH-3 study enrolling 12,737 patients showed that early, <3h, administration of tranexamic acid (TXA) decreased mortality in mild-moderate TBI patients. In accordance with large previous trials, thromboembolic complications were not increased. In view of the favourable safety profile of TXA and the devastating effects from intracranial bleeds, the authors argue that TXA be administered within 3h post-injury to moderate-severe TBI patients, and in mild TBI to those with intracranial haemorrhage on acute CT.
    • Accession Number:
      0 (Antifibrinolytic Agents)
      6T84R30KC1 (Tranexamic Acid)
    • Publication Date:
      Date Created: 20201006 Date Completed: 20201123 Latest Revision: 20220531
    • Publication Date:
      20221213
    • Accession Number:
      33021328